Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft für klinische Spezialpräparate mbH announced that they have obtained manufacturing and marketing approval from the… read more.
Obesity is associated with worse flare symptoms and worse quality of life among patients with early rheumatoid arthritis, researchers reported on Nov. 12, 2023 at ACR Convergence 2023,… read more.
New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, shows that treating rheumatoid arthritis with hydroxychloroquine (HCQ) reduced the risk of nonalcoholic fatty… read more.
Galapagos NV and Alfasigma S.p.A. announced that they have signed a letter of intent contemplating a transfer of the Jyseleca business to Alfasigma, including the European and UK… read more.
Galapagos revealed that it is weighing up all options for its only approved product, the JAK inhibitor Jyseleca. Galapagos has disclosed its financials for the first half 2023… read more.
Anxiety and depression are the mental health issues most commonly associated with inflammatory arthritis, and it is well-established that there is a link between mental health issues and… read more.
A research team, led by Professor Sung Ho Park in the Department of Biological Sciences at UNIST announced the results of a study on osteoblasts that damage joint bones… read more.
Breathing in common workplace dusts and fumes from agents such as vapours, gases, and solvents, may heighten the risk of developing rheumatoid arthritis, suggests research published online in… read more.
The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests. The study, published today in The Lancet… read more.
Researchers at Baylor College of Medicine and collaborating institutions discovered that the rheumatoid arthritis drug auranofin can potentially be repurposed to improve diabetes-associated symptoms. The study, which was… read more.
Scientists have identified a protein known as sulfatase-2 that plays a critical role in the damage caused by rheumatoid arthritis. A chronic disease in which the immune system… read more.
Pfizer Inc. announced that the FDA has accepted for review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for Abrilada (adalimumab-afzb) as an interchangeable biosimilar… read more.